Rhieos-Ventures

What Rhieos-Ventures does

Rhieos-Ventures is a UK-based clinical research decision intelligence consultancy founded in 2013 by Larry Ajuwon, operating with a small team of 2-10 employees from a registered office in Tottenham, London. The company serves life sciences organizations with a portfolio that spans three interlocking offerings: the TrialValue platform (a web-based and API-accessible engine that predicts and benchmarks clinical study budgets, with an AI+ module claiming two-minute budget outputs), the Dealligence framework (a structured methodology for biopharmaceutical clinical development negotiations covering co-development, outsourcing, licensing, governance, partnerships, procurement, and clinical research), and CTAide (a clinical trial agreement analysis tool co-developed with Engage Clinical Contract Solutions that flags one-sided clauses, quantifies risk, and visualizes balance across sponsors, CROs, and institutions).

The company monetizes through a hybrid model combining professional services (clinical strategy, business development, negotiation coaching, and AI assurance consulting) with subscription and licensing revenue from TrialValue (annual billing, API licensing and customization) and royalty/licensing arrangements for CTAide. Customer segments are diversified across biotech and pharmaceutical companies, research institutions, hospitals, patient advocacy groups (with a particular focus on sickle cell disease in Africa), and global/public health bodies. Distribution mixes direct enterprise consulting with a self-service platform at trialvalueapp.com and thought leadership content distributed through a blog, industry publications such as Applied Clinical Trials, and the RHIEOS Fireside Decision Room private discussion series.

Rhieos also operates non-commercial initiatives including the Nigeria Sickle Cell Disease Registry (in partnership with Sickle Cell Foundation Nigeria since 2018, aligned with WHO Africa recommendations) and serves as corporate trustee for Afrelib Trust, a charitable entity focused on education and literacy in Africa. The firm is privately held with no disclosed external institutional investors and is operated under founder control.

Name

Rhieos-Ventures

Legal name

Rhieos-Ventures

Website

https://rhieosventures.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Rhieos-Ventures is a UK-based clinical research decision intelligence consultancy serving life sciences organizations with the TrialValue budget prediction platform, the Dealligence negotiation framework, and CTAide contract analysis tool, supplemented by advisory services for biotech, pharma, and patient groups.

Ownership category

akta.pro rank

Product category

Clinical Research Decision Intelligence

NAICS

Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Financial Management & Payments (Site Budgeting) (HLAGACAM)

akta.pro secondary industries

Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Clinical trial budgeting
• Clinical research consulting
• Contract analysis tools
• Negotiation frameworks
• Decision intelligence

Headquarters

HQ city

Tottenham

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. TrialValue Platform Services: Provides financial modelling, budget prediction, API model licensing and customization, cost analysis, and financial negotiation support through the TrialValue platform. Targets investors, sponsors, patients and teams.
2. Clinical Strategy and Consulting Services: Advisory and consulting services including clinical development planning, program design, protocol design, feasibility studies, budget models, AI assurance, compliance advice, and negotiation coaching.
3. Business Development and Partnering Services: Services helping teams develop opportunities including business case development, financial valuation, funding plans, contracts, partnering strategy, alliance management, and negotiation workshops.
4. Contract Design and Assessment Tools: CTAide and Clinical Trial Agreement Inventory tools developed in collaboration with Engage Clinical Contract Solutions for clinical trial agreement review and assessment.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Rhieos-Ventures provides clinical research decision intelligence through a combination of consulting services and proprietary software platforms. Core offerings include TrialValue (a clinical trial budget prediction and benchmarking platform), TrialValue AI+ (an AI-enhanced budget modeling tool), Dealligence (a negotiation framework for biopharmaceutical collaborations), and CTAide (a clinical trial agreement analysis tool). The firm also delivers strategic consulting across clinical development planning, business development and partnering, and healthcare solutions delivery for life science organizations.

Product overview

Rhieos-Ventures offers a portfolio of decision intelligence products and consulting services for clinical research. The core platform is TrialValue, a web-based clinical study cost prediction and benchmarking tool available via web application and API. TrialValue AI+ is their AI-enhanced module for accelerated budget prediction. Dealligence is a negotiation framework for clinical development collaborations, complemented by CTAide, a clinical trial agreement analysis tool. The company also provides strategic consulting services across clinical development strategy, business development and partnerships, and healthcare solutions delivery. Their initiatives include the Nigeria Sickle Cell Disease Registry and Afrelib Trust charitable work.

Differentiator

Problem solved

Functional benefit

Brands

• Dealligence: Practical framework for preparing, designing, planning, and conducting negotiations involving biopharmaceutical clinical development and access collaborations
• TrialValue
• CTAide

Products and services

• TrialValue A web-based decision support platform that predicts and benchmarks clinical study costs. Helps investors, sponsors, patients and teams improve program planning and resource allocation by accurately estimating study budgets and providing benchmarking against comparable trials.
• TrialValue AI+ AI-enhanced version of the TrialValue platform that uses predictive analytics to forecast clinical study costs, benchmark budgets, and model financial scenarios in approximately 2 minutes. Supports sponsors, investors, and teams with rapid program planning and resource allocation under various feasibility scenarios.
• Dealligence A practical and actionable negotiation framework for biopharmaceutical clinical development and access collaborations. Focus areas include co-development, outsourcing, licensing, governance, partnerships, procurement, and clinical research.
• CTAide A digital tool that analyzes clinical trial agreements for completeness, balance, and usability. Flags one-sided or ambiguous clauses, quantifies risk exposure, and visualizes balance across sponsor, CRO, and institution stakeholders.
• Clinical Strategy and Planning Services Strategic consulting services covering clinical development planning, program design, feasibility studies, protocol design, study planning, budget modeling, AI assurance, and GxP compliance advice for life science organizations.
• Partnerships and Business Development Services Advisory services supporting business case development, financial valuation, funding plans, contract and alliance strategy, AI assurance for GxP operations, and negotiation coaching and workshops for clinical development and partnering teams.
• Healthcare Solutions Delivery Services Healthcare access solutions covering preventive care, point-of-care diagnostics, digital health, rare and neglected disease programs, advocacy strategy, initiative delivery, and partnership management.

Quantifiable outcome

• TrialValue AI+ predicts and benchmarks study budgets in 2 minutes
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core, major and minor.

• Sickle Cell Foundation NigeriacoreStrategic or Co-development Partner · 31 October 2018Press release announced partnership to set up the first multi-centre Sickle Cell Disease registry in Nigeria. RHIEOS contributes to surveillance, research, and registry building efforts in West Africa as part of WHO Africa recommendations for national sickle-cell disease control programmes.
• Engage Clinical Contract SolutionscoreStrategic or Co-development PartnerCollaboration to develop CTAide - a Clinical Trial Agreement analysis tool that evaluates agreements for completeness, balance, and usability. Also jointly developed the Clinical Trial Agreement Inventory tool. Copyright 2025 RHIEOS Ventures Production in collaboration with Engage CCS.
• DealligencemajorGTM or Marketing PartnerDealligence is described as a practical framework for negotiations in biopharmaceutical clinical development. RHIEOS promotes Dealligence alongside their CTAide tool as complementary solutions enabling teams to meet collaboration goals. Focus areas include co-development, outsourcing, licensing, governance, partnerships, procurement, and clinical research.
• CTAidemajorGTM or Marketing PartnerCTAide is promoted as a digital companion to the Clinical Trial Agreement Inventory. RHIEOS Ventures collaborated with Engage Clinical Contract Solutions to develop CTAide, which analyzes clinical trial agreements for completeness, balance, and usability.
• Afrelib TrustcoreOthersRHIEOS Ventures serves as the corporate trustee for Afrelib Trust, a charitable entity focused on advancing education, literacy and building sustainable libraries in Africa.
• WHO AfricaminorOthersWHO Africa has recommended creation or strengthening of national sickle-cell disease control programmes. RHIEOS SCD registry initiative aligns with WHO Africa's essential areas including advocacy, prevention, early detection, surveillance, research, and community education.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Trial Library: Trial Library offers a clinical trial feasibility and site selection platform with budget benchmarking, directly overlapping TrialValue's core use case of helping sponsors predict and benchmark clinical study costs.
• Halloran Consulting Group: Halloran is a life sciences consulting firm supporting biotech and pharma with clinical development strategy, program design, and quality/GxP advisory — closely overlapping RHIEOS's clinical strategy and AI assurance services.
• Cytel: Cytel provides clinical trial design, biostatistics, and adaptive trial analytics software and services. It competes with RHIEOS in clinical research decision intelligence and trial economics support.

Broad incumbents

• ICON plc: ICON is a global CRO offering clinical research services across all phases along with consulting and analytics, covering the outsourced clinical operations and economics advisory space where RHIEOS competes.
• Veeva Systems: Veeva's Vault CTMS, eTMF, and clinical operations suites cover clinical trial operations and document/agreement management, broadly adjacent to CTAide and TrialValue's contracting and economics remit.
• Medidata (Dassault Systèmes): Medidata provides the industry's leading EDC, CTMS, eCOA and clinical trial analytics platform, broadly encompassing trial informatics that RHIEOS's TrialValue and CTAide offerings touch on.
• IQVIA: IQVIA combines CRO services with real-world evidence, analytics, and technology offerings, addressing many of the clinical development strategy, RWE, and trial economics problems RHIEOS targets.
• Charles River Associates: CRA's Life Sciences practice provides management and economic consulting to pharma and biotech on clinical development, pricing, and market access — broadly comparable to RHIEOS's advisory services.
• Oracle Health Sciences: Oracle's Clinical One and Siebel CTMS provide broad clinical trial technology infrastructure, including budgeting, monitoring, and trial management — overlapping with RHIEOS's clinical trial financial management focus.

Emerging players

• Trifecta Clinical: Trifecta Clinical is a niche clinical operations consultancy offering CRO selection, contract negotiation, and outsourcing advisory — overlapping closely with RHIEOS's Dealligence and CTAide offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rhieos-Ventures